Tumor Burden
Tumor Burden - Related Videos
02:03
Assessing Bacterial Burden in the Mouse Spleen for Infection Studies
0 Views •
2026
Source: Madenspacher, J. H. and Fessler, M. B. A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice. J. Vis. Exp. (2016)This video demonstrates the process of quantifying bacterial load in the spleen of an infected mouse to assess the severity of infection. The homogenized spleen is serially diluted and plated to determine total bacterial burden. The resulting data provide insights into host-pathogen interactions within...
03:23
Measurement of the In Vivo Burden of Bacteria Expressing Luciferase in an Insect Larva
0 Views •
2025
This video showcases the in vivo bacterial burden measurement using Bacillus Calmette-Guérin, BCG, lux-infected insect larvae. The process involves larval homogenization, treatment with a luciferase substrate, and bioluminescence measurement to determine relative light units that correlate with bacterial burden.
03:46
Malassezia-Induced Skin Inflammation and Fungal Burden Analysis in a Murine Model
0 Views •
2025
This video demonstrates Malassezia-induced skin infection in mice. Malassezia oil suspension is applied over the wounded ear, triggering inflammation and swelling of the ear tissue. Later, the ears are dissected, homogenized, and spread on an agar plate for growth. The number of colonies indicates the fungal burden resulting from skin inflammation.
04:29
Monitoring Neutrophil Recruitment Dynamics and Bacterial Burden at the Infection Site in a Murine Model
0 Views •
2025
This video demonstrates in vivo imaging to study the neutrophil recruitment dynamics at an infection site in an immunocompromised, transgenic mouse with GFP-expressing neutrophils. It involves injecting luminescent bacteria to cause an infection. This leads to neutrophil recruitment to the infection site, whose tracking is done by imaging.
07:12
Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models
0 Views •
Cited by 29 •
2016
Bioluminescence imaging is a well-known tool for localizing tumors and metastases, but quantification of these images often requires complex calculations and particular instruments. We describe the easy-to-use luminoscore method, based on precise acquisition conditions, requiring no calculations, and enabling tumor burden and treatment response to be monitored in mouse models.
FAQs
Tumor burden can be characterized through several complementary dimensions, including tumor size, the number of tumors, and the extent of disease. Imaging may provide measurements of lesions, while physical examination, pathology, and biomarkers contribute additional evidence. Combining these sources helps researchers describe disease more fully than relying on a single measurement alone.
A single tumor-burden measurement describes disease at one point in time, whereas repeated assessments show whether the cancer is growing or becoming smaller. This longitudinal comparison helps distinguish a changing disease state from a baseline condition and supports evaluation of how the disease responds during research or treatment-related observation.
Tumor burden provides information that helps characterize disease severity, making it relevant to staging and prognosis. Measurements of tumor extent, number, or size can be considered alongside other clinical and pathological information. In cancer research, this relationship helps investigators examine how the amount of disease relates to expected outcomes and disease progression.
Researchers interpret changes in tumor burden as evidence about whether a therapy is controlling disease, reducing it, or failing to produce the desired effect. Decreasing measurements may support a response, while increasing measurements may prompt further investigation. Repeated assessments therefore provide quantitative information for evaluating treatment effects rather than relying only on a single observation.
An assessment begins by selecting appropriate evidence, such as imaging, physical examination, pathology, or biomarkers. Investigators then record the relevant tumor measurements or findings and compare them with later assessments. The resulting changes can be used to characterize disease, evaluate treatment response, or support a study endpoint, depending on the research question.
Imaging, physical examination, pathology, and biomarkers each offer a way to assess tumor burden. Their roles may differ according to the disease and study design, so researchers can use more than one source to support characterization. This multimodal approach allows measurements of tumors or cancer-related findings to be considered together when interpreting disease status.
Tumor burden can serve as a quantitative endpoint because investigators can record its extent and compare it across time or experimental conditions. In preclinical and clinical studies, these comparisons help evaluate whether an intervention controls or reduces disease. The measurements also support structured interpretation of treatment effects and decisions about further investigation.
Changes in tumor burden provide evidence that can guide what happens next in a research or clinical assessment. Measurements suggesting control or reduction may support continued evaluation, whereas evidence of growth may indicate a need for additional investigation. These decisions are based on comparisons over time, connecting tumor-burden data with disease monitoring and treatment planning.